AMLX
Amylyx Pharmaceuticals, Inc.
There isn't enough reported data to score AMLX yet.
AMLX Fundamentals
| Metric | Status |
|---|---|
| Weak | |
| Under pressure | |
| Unavailable | |
| Strong |
AMLX's balance sheet is currently strong, but its revenue and profitability are under pressure. There isn't enough data to rate its cash flow.
AMLX PE Valuation
AMLX has no meaningful PE right now: it lost money over the past year.
AMLX Forward outlook
There aren't enough analyst estimates for AMLX to show an outlook.
AMLX Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$1.42 | +$0.38 |
| Q2 2026 | -$1.41 | +$1.09 |
| Q1 2026 | -$1.48 | +$1.63 |
| Q4 2025 | -$1.53 | +$2.91 |
| Q3 2025 | -$1.80 | +$2.02 |
| Q2 2025 | -$2.50 | -$0.05 |
| Q1 2025 | -$3.11 | -$2.04 |
| Q4 2024 | -$4.44 | -734% |
AMLX is still losing money, but far less than before: $1.42 per share over the past year, against $4.44 at its worst in late 2024.
AMLX Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2024 | $416K | -100% |
| Q1 2024 | $88.6M | +24% |
| Q4 2023 | $108.4M | +396% |
| Q3 2023 | $102.7M | +29666% |
AMLX's revenue has slid since its 2023 peak: $0 last quarter, down 100% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2024 | -18188% | -18206 points |
| Q1 2024 | -138% | -135 points |
| Q4 2023 | 1.8% | +206 points |
| Q3 2023 | 18% | +15868 points |
| Q2 2023 | 21% | N/A |
| Q1 2023 | -2.9% | N/A |
| Q4 2022 | -204% | N/A |
| Q3 2022 | -15850% | N/A |
AMLX's operating margin was −18188% last quarter, down 18208 points from the same quarter a year ago, near the bottom of its range since 2022.
AMLX Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$33.7M | -$3.3M |
| Q4 2025 | -$28M | +$31M |
| Q3 2025 | -$30.4M | +$11.2M |
| Q2 2025 | -$25.3M | +$41.4M |
| Q1 2025 | -$39.8M | -$39.3M |
| Q4 2024 | -$59M | -547% |
| Q3 2024 | -$41.6M | -$36M |
| Q2 2024 | -$66.7M | -900% |
AMLX has burned cash in almost every quarter: −$117M over the past year, against −$207M the year before.
AMLX Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +7% | +7.7M shares |
| 1 year | +27% | +25.6M shares |
| 3 years | +71% | +49.2M shares |
| 5 years | +115% | +63.7M shares |
AMLX has 119M diluted shares, up 27% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2024 | — |
| Q2 2024 | — |
| Q4 2021 | — |
| Q3 2021 | — |
| Q2 2021 | — |
| Q1 2021 | — |
| Q4 2020 | — |
AMLX Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q4 2023 | -4.3x | Net Cash |
AMLX has more cash than debt.
AMLX Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 61.1 | Neutral |
| Stochastic | 45.5 | Neutral |
AMLX's weekly RSI is 61 (neutral) and its Stochastic is 46 (neutral).
AMLX PE vs Healthcare Sector
| Metric | AMLX | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
AMLX has no meaningful PE right now: it lost money over the past year.
AMLX Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $28.4 | 5.1% above |
| 20 week MA | $26.8 | 12% above |
| 50 week MA | $19.4 | 54% above |
| 100 week MA | $13.4 | 124% above |
| 200 week MA | $14.0 | 114% above |
AMLX has climbed back above all five of its weekly moving averages, and it's now 114% above its 200-week average.
AMLX Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2022 | $18.1 | $35.6 | +97% |
| 2023 | $35.6 | $14.7 | -59% |
| 2024 | $14.7 | $3.87 | -74% |
| 2025 | $3.87 | $12.3 | +219% |
| 2026 YTD | $12.3 | $29.9 | +142% |
AMLX's yearly returns have swung widely, from +219% in 2025 to −74% in 2024. It's up 142% so far in 2026.